- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Poster at ACG Shares Good News for Patients With Ulcerative Colitis
(AUDIO) What is the natural history of systemic corticosteroid therapy in ulcerative colitis? Insights here from Dr Nabeel Khan, Assistant Professor of Medicine in Gastroenterology & Hepatology at Tulane Medical Center-author of a new study on this topic.
Ulcerative colitis, one of the two major types of inflammatory bowel disease, affects about 1 million people in the US. Somewhat more common in women than in men, its age of onset peaks at 15 to 25 years and then again at 55 to 65 years. Although the cause is unknown for this chronic illness, it can have a profound emotional and social impact on those affected.
So what can you do help your patients? Dr Nabeel Khan, Assistant Professor of Medicine in Gastroenterology & Hepatology at Tulane Medical Center, and colleagues explored the natural history of systemic corticosteroid therapy in ulcerative colitis in a nationwide retrospective cohort from the Veterans Affairs Healthcare System. Their data are being presented at the American College of Gastroenterology’s 2012 Annual Scientific Meeting in Las Vegas, and he joins us here to shed some light on this topic.
Poster at ACG Shares Good News for Patients With Ulcerative Colitis
Clinical Tips for Using Antibiotics and Corticosteroids in IBD
January 5th 2013The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.
